United States - English - NLM (National Library of Medicine)

orchidpharma inc - cefpodoxime proxetil (unii: 2tb00a1z7n) (cefpodoxime - unii:7r4f94tvgy) - cefpodoxime 100 mg - cefpodoxime proxetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. recommended dosages, durations of therapy, and applicable patient populations vary among these infections. please see dosage and administration for specific recommendations. acute otitis media caused by streptococcus pneumoniae (excluding penicillin-resistant strains), streptococcus pyogenes, haemophilus influenzae (including beta- lactamase-producing strains), or moraxella (branhamella) catarrhalis (including beta- lactamase-producing strains). pharyngitis and/or tonsillitis caused by streptococcus pyogenes . note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefpodoxime proxetil tablets are generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefpodoxime pro

United States - English - NLM (National Library of Medicine)

putney inc - cefpodoxime proxetil (unii: 2tb00a1z7n) (cefpodoxime - unii:7r4f94tvgy) - cefpodoxime 100 mg - cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. recommended dosages, durations of therapy, and applicable patient populations vary among these infections. please see dosage and administration for specific recommendations. acute otitis media caused by streptococcus pneumoniae (excluding penicillin-resistant strains), streptococcus pyogenes, haemophilus influenzae (including beta-lactamase-producing strains), or moraxella (branhamella) catarrhalis (including beta-lactamase-producing strains). pharyngitis and/or tonsillitis caused by streptococcus pyogenes . note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefpodoxime proxetil for the pro

United States - English - NLM (National Library of Medicine)

sandoz inc - cefpodoxime proxetil (unii: 2tb00a1z7n) (cefpodoxime - unii:7r4f94tvgy) - cefpodoxime 50 mg in 5 ml - cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. recommended dosages, durations of therapy, and applicable patient populations vary among these infections. please see dosage and administration for specific recommendations. acute otitis media caused by streptococcus pneumoniae (excluding penicillin-resistant strains), streptococcus pyogenes, haemophilus influenzae (including beta-lactamase-producing strains), or moraxella (branhamella) catarrhalis (including beta-lactamase-producing strains). pharyngitis and/or tonsillitis caused by streptococcus pyogenes. note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefpodoxime proxetil for the prop

United States - English - NLM (National Library of Medicine)

gen-source rx - cefpodoxime proxetil (unii: 2tb00a1z7n) (cefpodoxime - unii:7r4f94tvgy) - cefpodoxime 100 mg - cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.  recommended dosages, durations of therapy, and applicable patient populations vary among these infections. please see dosage and administration for specific recommendations. acute otitis media caused by streptococcus pneumoniae (excluding penicillin-resistant strains), streptococcus pyogenes , haemophilus influenzae (including beta-lactamase-producing strains), or moraxella (branhamella) catarrhalis (including beta-lactamase-producing strains).  pharyngitis and/or tonsillitis caused by streptococcus pyogenes . note:  only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefpodoxime proxetil is generally effective in the eradication of  streptococci from the oropharynx. however, data establishing the efficacy of cefpodoxim

United States - English - NLM (National Library of Medicine)

putney, inc. - cefpodoxime proxetil (unii: 2tb00a1z7n) (cefpodoxime - unii:7r4f94tvgy) - cefpodoxime 100 mg - indications cefpodoxime proxetil tablets are indicated for the treatment of skin infections (wounds and abscesses) in dogs caused by susceptible strains of staphylococcus intermedius , staphylococcus aureus , streptococcus canis (group g, β hemolytic), escherichia coli, pasteurella multocida, and proteus mirabilis. contraindications cefpodoxime proxetil is contraindicated in dogs with known allergy to cefpodoxime or to the β-lactam (penicillins and cephalosporins) group of antibiotics.

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - cefpodoxime proxetil (unii: 2tb00a1z7n) (cefpodoxime - unii:7r4f94tvgy) - cefpodoxime 200 mg - cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.  recommended dosages, durations of therapy, and applicable patient populations vary among these infections. please see dosage and administration for specific recommendations. acute otitis media caused by streptococcus pneumoniae (excluding penicillin-resistant strains), streptococcus pyogenes , haemophilus influenzae (including beta-lactamase-producing strains), or moraxella (branhamella) catarrhalis (including beta-lactamase-producing strains).  pharyngitis and/or tonsillitis caused by streptococcus pyogenes . note:  only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefpodoxime proxetil

United States - English - NLM (National Library of Medicine)

sandoz inc - cefpodoxime proxetil (unii: 2tb00a1z7n) (cefpodoxime - unii:7r4f94tvgy) - cefpodoxime 100 mg - cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. recommended dosages, durations of therapy, and applicable patient populations vary among these infections. please see dosage and administration for specific recommendations. acute otitis media caused by streptococcus pneumoniae (excluding penicillin-resistant strains), streptococcus pyogenes, haemophilus influenzae (including beta-lactamase-producing strains), or moraxella (branhamella) catarrhalis (including beta-lactamase-producing strains). pharyngitis and/or tonsillitis caused by streptococcus pyogenes . note: only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. however, data establishing the efficacy of cefpodoxime proxetil for the pr

United States - English - NLM (National Library of Medicine)

cronus pharma llc - cefpodoxime proxetil (unii: 2tb00a1z7n) (cefpodoxime - unii:7r4f94tvgy) - cefpodoxime 100 mg - cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.  recommended dosages, durations of therapy, and applicable patient populations vary among these infections. please see dosage and administration for specific recommendations. acute otitis media caused by streptococcus pneumoniae (excluding penicillin-resistant strains), streptococcus pyogenes , haemophilus influenzae (including beta-lactamase-producing strains), or moraxella (branhamella) catarrhalis (including beta-lactamase-producing strains).  pharyngitis and/or tonsillitis caused by streptococcus pyogenes . note:  only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefpodoxime proxetil is generally effective in the eradication of  streptococci from the oropharynx. however, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. community-acquired pneumonia  caused by s. pneumoniae or h. influenzae (including beta-lactamase-producing strains).  acute bacterial exacerbation of chronic bronchitis  caused by s. pneumoniae , h. influenzae (non-beta-lactamase-producing strains only), or m. catarrhalis . data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of h. influenzae .  acute, uncomplicated urethral and cervical gonorrhea   caused by neisseria gonorrhoeae (including penicillinase-producing strains).  acute, uncomplicated ano-rectal infections in women   due to neisseria gonorrhoeae (including penicillinase-producing strains).  note: the efficacy of cefpodoxime in treating male patients with rectal infections caused by n. gonorrhoeae has not been established. data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to n. gonorrhoeae in men or women.  uncomplicated skin and skin structure infections  caused by staphylococcus aureus (including penicillinase-producing strains) or streptococcus pyogenes . abscesses should be surgically drained as clinically indicated.  note:  in clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. the effective therapeutic dose for skin infections was higher than those used in other recommended indications. (see dosage and administration .)  acute maxillary sinusitis   caused by haemophilus influenzae (including beta-lactamase-producing strains), streptococcus pneumoniae , and moraxella catarrhalis .  uncomplicated urinary tract infections (cystitis)   caused by escherichia coli, klebsiella pneumoniae, proteus mirabilis , or staphylococcus saprophyticus .  note:  in considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents. (see clinical studies section.)  appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. therapy may be instituted while awaiting the results of these studies. once these results become available, antimicrobial therapy should be adjusted accordingly.  to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil and other antibacterial drugs, cefpodoxime proxetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefpodoxime proxetil is contraindicated in patients with a known allergy to cefpodoxime or to the cephalosporin group of antibiotics.

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - cefpodoxime proxetil (unii: 2tb00a1z7n) (cefpodoxime - unii:7r4f94tvgy) - cefpodoxime 100 mg - cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.  recommended dosages, durations of therapy, and applicable patient populations vary among these infections. please see dosage and administration for specific recommendations. acute otitis media caused by streptococcus pneumoniae (excluding penicillin-resistant strains), streptococcus pyogenes , haemophilus influenzae (including beta-lactamase-producing strains), or moraxella (branhamella) catarrhalis (including beta-lactamase-producing strains).  pharyngitis and/or tonsillitis caused by streptococcus pyogenes . note:  only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefpodoxime proxetil is generally effective in the eradication of  streptococci from the oropharynx. however, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. community-acquired pneumonia  caused by s. pneumoniae or h. influenzae (including beta-lactamase-producing strains).  acute bacterial exacerbation of chronic bronchitis  caused by s. pneumoniae , h. influenzae (non-beta-lactamase-producing strains only), or m. catarrhalis . data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of h. influenzae .  acute, uncomplicated urethral and cervical gonorrhea   caused by neisseria gonorrhoeae (including penicillinase-producing strains).  acute, uncomplicated ano-rectal infections in women   due to neisseria gonorrhoeae (including penicillinase-producing strains).  note: the efficacy of cefpodoxime in treating male patients with rectal infections caused by n. gonorrhoeae has not been established. data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to n. gonorrhoeae in men or women.  uncomplicated skin and skin structure infections  caused by staphylococcus aureus (including penicillinase-producing strains) or streptococcus pyogenes . abscesses should be surgically drained as clinically indicated.  note:  in clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. the effective therapeutic dose for skin infections was higher than those used in other recommended indications. (see dosage and administration .)  acute maxillary sinusitis   caused by haemophilus influenzae (including beta-lactamase-producing strains), streptococcus pneumoniae , and moraxella catarrhalis .  uncomplicated urinary tract infections (cystitis)   caused by escherichia coli, klebsiella pneumoniae, proteus mirabilis , or staphylococcus saprophyticus .  note:  in considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents. (see clinical studies section.)  appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. therapy may be instituted while awaiting the results of these studies. once these results become available, antimicrobial therapy should be adjusted accordingly.  to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil and other antibacterial drugs, cefpodoxime proxetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefpodoxime proxetil is contraindicated in patients with a known allergy to cefpodoxime or to the cephalosporin group of antibiotics.

United States - English - NLM (National Library of Medicine)

northstar rx llc - cefpodoxime proxetil (unii: 2tb00a1z7n) (cefpodoxime - unii:7r4f94tvgy) - cefpodoxime 100 mg - cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below.  recommended dosages, durations of therapy, and applicable patient populations vary among these infections. please see dosage and administration for specific recommendations. acute otitis media caused by streptococcus pneumoniae (excluding penicillin-resistant strains), streptococcus pyogenes , haemophilus influenzae (including beta-lactamase-producing strains), or moraxella (branhamella) catarrhalis (including beta-lactamase-producing strains).  pharyngitis and/or tonsillitis caused by streptococcus pyogenes . note:  only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. cefpodoxime proxetil is generally effective in the eradication of  streptococci from the oropharynx. however, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. community-acquired pneumonia  caused by s. pneumoniae or h. influenzae (including beta-lactamase-producing strains).  acute bacterial exacerbation of chronic bronchitis  caused by s. pneumoniae , h. influenzae (non-beta-lactamase-producing strains only), or m. catarrhalis . data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of h. influenzae .  acute, uncomplicated urethral and cervical gonorrhea   caused by neisseria gonorrhoeae (including penicillinase-producing strains).  acute, uncomplicated ano-rectal infections in women   due to neisseria gonorrhoeae (including penicillinase-producing strains).  note: the efficacy of cefpodoxime in treating male patients with rectal infections caused by n. gonorrhoeae has not been established. data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to n. gonorrhoeae in men or women.  uncomplicated skin and skin structure infections  caused by staphylococcus aureus (including penicillinase-producing strains) or streptococcus pyogenes . abscesses should be surgically drained as clinically indicated.  note:  in clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. the effective therapeutic dose for skin infections was higher than those used in other recommended indications. (see dosage and administration .)  acute maxillary sinusitis   caused by haemophilus influenzae (including beta-lactamase-producing strains), streptococcus pneumoniae , and moraxella catarrhalis .  uncomplicated urinary tract infections (cystitis)   caused by escherichia coli, klebsiella pneumoniae, proteus mirabilis , or staphylococcus saprophyticus .  note:  in considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents. (see clinical studies section.)  appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. therapy may be instituted while awaiting the results of these studies. once these results become available, antimicrobial therapy should be adjusted accordingly.  to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil and other antibacterial drugs, cefpodoxime proxetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefpodoxime proxetil is contraindicated in patients with a known allergy to cefpodoxime or to the cephalosporin group of antibiotics.